Bound Therapeutics LLC executed an exclusive license from Thomas Jefferson University to use our novel platform technology (Compositions and Methods of Using MicroRNA Inhibitors, PCT/US2015/015681) to develop microRNA therapeutics and diagnostics. Preliminary data showed that our proprietary lead compound designed using our platform reversed off-target effects from conventionally designed microRNA
-blocking agents in a triple negative breast cancer cell model. Bound Therapeutics agents achieve cancer cell-specific delivery of the lead compound through receptor-mediated endocytosis by conjugation with a small peptide (Wickstrom and Basu, Peptide Nucleic Acid Conjugates. Our platform yields single molecule agents that circulate and enter cells with no need for liposome or nanoparticle formulations. We will optimize agents for the needs of each target and customer. Triple negative breast cancer (TNBC) is an aggressive form of breast cancer at a later stage. TNBC accounts for 10-15% of all breast cancers, striking and killing about 28,000 American women each year. There is a tremendous gap in treating TNBC due to the lack of effective targeted agents. The only available supplemental option for chemotherapy, Avastin, was invalidated by FDA for the breast cancer indication in 2011 as a result of poor clinical outcome and safety issues. Drugs in the late stage pipeline are all poly(ADP-ribose) polymerase (PARP) inhibitors. These are only modestly effective in treating a small subset of TNBC patients. Currently only routine chemotherapy is the standard of care, with significant side effects that aggravate the suffering of patients. Therefore, a new molecular therapeutic agent that works in conjunction with chemotherapy with greater
efficacy, specificity, and safety will bridge the gap in
TNBC therapy. Bound Therapeutics designs novel molecular targeting agents that comprise an attractive option for patients. We minimize side effects through a platform technology that enables cancer cell-specific delivery of all compounds. Faster response, decreased dosage, and decreased side effects will reduce the longterm cost of disease management.
